{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:35:44Z","timestamp":1790908544302,"version":"4.1.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01HL133290"],"award-info":[{"award-number":["R01HL133290"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01HL119234"],"award-info":[{"award-number":["R01HL119234"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["13SDG16930103"],"award-info":[{"award-number":["13SDG16930103"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["K08HL116803"],"award-info":[{"award-number":["K08HL116803"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["R01HL136824"],"award-info":[{"award-number":["R01HL136824"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myelogenous leukaemia (CML). However, cardiotoxicity of these agents remains a serious concern. The underlying mechanism of these adverse cardiac effects is largely unknown. Delineation of the underlying mechanisms of TKIs associated cardiac dysfunction could guide potential prevention strategies, rescue approaches, and future drug design. This study aimed to determine the cardiotoxic potential of approved CML TKIs, define the associated signalling mechanism and identify potential alternatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this study, we employed a zebrafish transgenic BNP reporter line that expresses luciferase under control of the nppb promoter (nppb:F-Luciferase) to assess the cardiotoxicity of all approved CML TKIs. Our in vivo screen identified ponatinib as the most cardiotoxic agent among the approved CML TKIs. Then using a combination of zebrafish and isolated neonatal rat cardiomyocytes, we delineated the signalling mechanism of ponatinib-induced cardiotoxicity by demonstrating that ponatinib inhibits cardiac prosurvival signalling pathways AKT and extra-cellular-signal-regulated kinase (ERK), and induces cardiomyocyte apoptosis. As a proof of concept, we augmented AKT and ERK signalling by administration of Neuregulin-1\u03b2 (NRG-1\u03b2), and this prevented ponatinib-induced cardiomyocyte apoptosis. We also demonstrate that ponatinib-induced cardiotoxicity is not mediated by inhibition of fibroblast growth factor signalling, a well-known target of ponatinib. Finally, our comparative profiling for the cardiotoxic potential of CML approved TKIs, identified asciminib (ABL001) as a potentially much less cardiotoxic treatment option for CML patients with the T315I mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Herein, we used a combination of in vivo and in vitro methods to systematically screen CML TKIs for cardiotoxicity, identify novel molecular mechanisms for TKI cardiotoxicity, and identify less cardiotoxic alternatives.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cvr\/cvz006","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T15:10:19Z","timestamp":1546614619000},"page":"966-977","source":"Crossref","is-referenced-by-count":89,"title":["Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies"],"prefix":"10.1093","volume":"115","author":[{"given":"Anand P","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB#348A, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Glennon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB#348A, Nashville, TN, USA"},{"name":"Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh, School of Medicine, University of Pittsburgh Medical Center, 200 Lothrop, BST E1258, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Umbarkar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB#348A, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Gupte","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB#348A, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristi L","family":"Galindo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB#348A, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinkun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB#348A, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Force","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB#348A, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB#348A, Nashville, TN, USA"},{"name":"Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh, School of Medicine, University of Pittsburgh Medical Center, 200 Lothrop, BST E1258, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Lal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB#348A, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"2026041420133962700_cvz006-B1","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026041420133962700_cvz006-B2","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2026041420133962700_cvz006-B3","year":"2014"},{"key":"2026041420133962700_cvz006-B4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"2026041420133962700_cvz006-B5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"2026041420133962700_cvz006-B6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"2026041420133962700_cvz006-B7","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"2026041420133962700_cvz006-B8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"2026041420133962700_cvz006-B9","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"2026041420133962700_cvz006-B10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"2026041420133962700_cvz006-B11","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1158\/0008-5472.CAN-12-1276","article-title":"The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL","volume":"72","author":"Hantschel","year":"2012","journal-title":"Cancer Res"},{"key":"2026041420133962700_cvz006-B12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2026041420133962700_cvz006-B13","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminhematol.2006.12.007","article-title":"The biology of chronic myelogenous leukemia: implications for imatinib therapy","volume":"44","author":"Alvarez","year":"2007","journal-title":"Semin Hematol"},{"key":"2026041420133962700_cvz006-B14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"2026041420133962700_cvz006-B15","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/1078-0432.CCR-03-0155","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates","volume":"10","author":"Neville","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026041420133962700_cvz006-B16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"2026041420133962700_cvz006-B17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.leukres.2010.01.004","article-title":"Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies","volume":"34","author":"Wolf","year":"2010","journal-title":"Leuk Res"},{"key":"2026041420133962700_cvz006-B18","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"key":"2026041420133962700_cvz006-B19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"2026041420133962700_cvz006-B20","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"2026041420133962700_cvz006-B21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL","volume":"61","author":"Kamath","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026041420133962700_cvz006-B22","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"2026041420133962700_cvz006-B23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.drudis.2013.06.001","article-title":"The background, discovery and clinical development of BCR-ABL inhibitors","volume":"18","author":"Lambert","year":"2013","journal-title":"Drug Discov Today"},{"key":"2026041420133962700_cvz006-B24","doi-asserted-by":"crossref","first-page":"637059.","DOI":"10.1155\/2014\/637059","article-title":"Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation","volume":"2014","author":"Reinwald","year":"2014","journal-title":"Biomed Res Int"},{"key":"2026041420133962700_cvz006-B25","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"2026041420133962700_cvz006-B26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"2026041420133962700_cvz006-B27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"2026041420133962700_cvz006-B28","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"2026041420133962700_cvz006-B29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"2026041420133962700_cvz006-B30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"2026041420133962700_cvz006-B31","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","article-title":"Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant","volume":"53","author":"Huang","year":"2010","journal-title":"J Med Chem"},{"key":"2026041420133962700_cvz006-B32","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1634\/theoncologist.2015-0253","article-title":"Ponatinib: accelerated disapproval","volume":"20","author":"Gainor","year":"2015","journal-title":"Oncologist"},{"key":"2026041420133962700_cvz006-B33","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"2026041420133962700_cvz006-B34","year":"2018"},{"key":"2026041420133962700_cvz006-B35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2013.284531","article-title":"The accelerated approval of oncologic drugs: lessons from ponatinib","volume":"311","author":"Prasad","year":"2014","journal-title":"JAMA"},{"key":"2026041420133962700_cvz006-B36","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"key":"2026041420133962700_cvz006-B37","doi-asserted-by":"crossref","first-page":"31958","DOI":"10.18632\/oncotarget.24110","article-title":". Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway","volume":"9","author":"Ai","year":"2018","journal-title":"Oncotarget"},{"key":"2026041420133962700_cvz006-B38","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/10428194.2016.1239258","article-title":"Ponatinib reduces viability, migration, and functionality of human endothelial cells","volume":"58","author":"Gover-Proaktor","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2026041420133962700_cvz006-B39","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"2026041420133962700_cvz006-B40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nchembio732","article-title":"High-throughput assay for small molecules that modulate zebrafish embryonic heart rate","volume":"1","author":"Burns","year":"2005","journal-title":"Nat Chem Biol"},{"key":"2026041420133962700_cvz006-B41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/cvr\/cvr350","article-title":"In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signalling","volume":"93","author":"Becker","year":"2012","journal-title":"Cardiovasc Res"},{"key":"2026041420133962700_cvz006-B42","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1161\/CIRCRESAHA.111.255695","article-title":"A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity","volume":"109","author":"Cheng","year":"2011","journal-title":"Circ Res"},{"key":"2026041420133962700_cvz006-B43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/bs.mcb.2016.10.004","article-title":"Chemical screening in zebrafish for novel biological and therapeutic discovery","volume":"138","author":"Wiley","year":"2017","journal-title":"Methods Cell Biol"},{"key":"2026041420133962700_cvz006-B44","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1242\/dmm.006148","article-title":"Human cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in zebrafish","volume":"4","author":"Becker","year":"2011","journal-title":"Dis Model Mech"},{"key":"2026041420133962700_cvz006-B45","volume-title":"AVMA Guidelines for the Euthanasia of Animals: 2013 Edition","year":"2013"},{"key":"2026041420133962700_cvz006-B46","doi-asserted-by":"crossref","first-page":"eaaf2584","DOI":"10.1126\/scitranslmed.aaf2584","article-title":"High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells","volume":"9","author":"Sharma","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026041420133962700_cvz006-B47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/toxsci\/kfu215","article-title":"A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity","volume":"143","author":"Talbert","year":"2015","journal-title":"Toxicol Sci"},{"key":"2026041420133962700_cvz006-B48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026041420133962700_cvz006-B49","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/nature07396","article-title":"BAX activation is initiated at a novel interaction site","volume":"455","author":"Gavathiotis","year":"2008","journal-title":"Nature"},{"key":"2026041420133962700_cvz006-B50","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.275.5302.983","article-title":"Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis","volume":"275","author":"Sattler","year":"1997","journal-title":"Science"},{"key":"2026041420133962700_cvz006-B51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/bj3460561","article-title":"The PI3K-PDK1 connection: more than just a road to PKB","volume":"346 Pt 3","author":"Vanhaesebroeck","year":"2000","journal-title":"Biochem J"},{"key":"2026041420133962700_cvz006-B52","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/15216540600957438","article-title":"ERK1\/2 MAP kinases in cell survival and apoptosis","volume":"58","author":"Lu","year":"2006","journal-title":"IUBMB Life"},{"key":"2026041420133962700_cvz006-B53","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1093\/emboj\/19.23.6341","article-title":"The MEK1-ERK1\/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice","volume":"19","author":"Bueno","year":"2000","journal-title":"EMBO J"},{"key":"2026041420133962700_cvz006-B54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCRESAHA.115.308238","article-title":"DUSP8 regulates cardiac ventricular remodeling by altering ERK1\/2 signaling","volume":"119","author":"Liu","year":"2016","journal-title":"Circ Res"},{"key":"2026041420133962700_cvz006-B55","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCRESAHA.110.231514","article-title":"Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth","volume":"108","author":"Kehat","year":"2011","journal-title":"Circ Res"},{"key":"2026041420133962700_cvz006-B56","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3892\/or.2013.2386","article-title":"Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1","volume":"29","author":"Ren","year":"2013","journal-title":"Oncol Rep"},{"key":"2026041420133962700_cvz006-B57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2012.066407","article-title":"Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"2026041420133962700_cvz006-B58","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2026041420133962700_cvz006-B59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/leu.2012.188","article-title":"Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities","volume":"27","author":"Ren","year":"2013","journal-title":"Leukemia"},{"key":"2026041420133962700_cvz006-B60","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/01.RES.0000012702.90501.8D","article-title":"Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection","volume":"90","author":"Baines","year":"2002","journal-title":"Circ Res"},{"key":"2026041420133962700_cvz006-B61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0008-6363(01)00294-2","article-title":"Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation","volume":"51","author":"Brar","year":"2001","journal-title":"Cardiovasc Res"},{"key":"2026041420133962700_cvz006-B62","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0008-6363(01)00531-4","article-title":"Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion","volume":"53","author":"Liao","year":"2002","journal-title":"Cardiovasc Res"},{"key":"2026041420133962700_cvz006-B63","doi-asserted-by":"crossref","first-page":"576.","DOI":"10.1016\/j.jacbts.2016.09.005","article-title":"A phase I, single ascending dose study of cimaglermin alfa (Neuregulin 1\u03b23) in patients with systolic dysfunction and heart failure","volume":"1","author":"Lenihan","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2026041420133962700_cvz006-B64","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","article-title":"Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity","volume":"105","author":"Sawyer","year":"2002","journal-title":"Circulation"},{"key":"2026041420133962700_cvz006-B65","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.yexcr.2007.02.007","article-title":"Inhibition of ErbB2\/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes","volume":"313","author":"Pentassuglia","year":"2007","journal-title":"Exp Cell Res"},{"key":"2026041420133962700_cvz006-B66","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.yjmcc.2003.09.012","article-title":"Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase\/Akt","volume":"35","author":"Fukazawa","year":"2003","journal-title":"J Mol Cell Cardiol"},{"key":"2026041420133962700_cvz006-B67","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"2026041420133962700_cvz006-B68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nchembio760","article-title":"Allosteric inhibitors of Bcr-abl-dependent cell proliferation","volume":"2","author":"Adrian","year":"2006","journal-title":"Nat Chem Biol"},{"key":"2026041420133962700_cvz006-B69","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.0000061912.88753.87","article-title":"Drugs that induce repolarization abnormalities cause bradycardia in zebrafish","volume":"107","author":"Milan","year":"2003","journal-title":"Circulation"},{"key":"2026041420133962700_cvz006-B70","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1152\/physrev.00024.2010","article-title":"Myocardial AKT: the omnipresent nexus","volume":"91","author":"Sussman","year":"2011","journal-title":"Physiol Rev"},{"key":"2026041420133962700_cvz006-B71","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/01.CIR.104.3.330","article-title":"Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo","volume":"104","author":"Matsui","year":"2001","journal-title":"Circulation"},{"key":"2026041420133962700_cvz006-B72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yjmcc.2004.11.005","article-title":"Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt","volume":"38","author":"Matsui","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"2026041420133962700_cvz006-B73","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4161\/cc.2.3.381","article-title":"Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival","volume":"2","author":"Matsui","year":"2003","journal-title":"Cell Cycle"},{"key":"2026041420133962700_cvz006-B74","doi-asserted-by":"crossref","first-page":"12333","DOI":"10.1073\/pnas.172376399","article-title":"Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice","volume":"99","author":"Condorelli","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026041420133962700_cvz006-B75","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-1-4939-3661-8_13","article-title":"Chronic myeloid leukemia (CML) mouse model in translational research","volume":"1438","author":"Peng","year":"2016","journal-title":"Methods Mol Biol"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/115\/5\/966\/28324902\/cvz006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/115\/5\/966\/28324902\/cvz006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:23:15Z","timestamp":1776212595000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/115\/5\/966\/5284910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":75,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,1,10]]},"published-print":{"date-parts":[[2019,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvz006","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,15]]},"published":{"date-parts":[[2019,1,10]]}}}